Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited
TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

INSIDE INFORMATION
UPDATE ON WINDING-UP PETITION

This announcement is made by TATA Health International Holdings Limited (the "**Company**") under Rules 13.09(2)(a) and 13.25(1)(b) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 17 August 2026 in relation to the winding-up petition filed by a former independent non-executive director of the Company, Mr. Tao Chi Keung against the Company (the "**Announcement**"). Unless otherwise stated, capitalised terms herein shall have the same meanings as those defined in the Announcement.

UPDATE ON THE PETITION

The Company wishes to update the shareholders and potential investors of the Company that following an assessment of the then performance of the Petitioner as the Company's independent non-executive director as well as the remuneration payable to him, the Company and the Petitioner had reached a settlement arrangement. As of the date of this announcement, the Company has settled the outstanding director's emolument under the Claim in full as referred to in the Announcement. In this connection, the solicitors for each of the Petitioner and the Company have signed a consent summons dated 15 September 2026 to seek an order by consent that, *inter alia*, the Petitioner do have leave to withdraw the Petition, and the hearing of the Petition fixed on 21 October 2026 be vacated (the "**Consent Summons**"). The Consent Summons has been filed with the High Court.

The Company will make further announcement as soon as an order in terms of the Consent Summons is to be received from the High Court.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Executive Director

Hong Kong, 27 November 2026

As at the date of this announcement, the Board comprises an executive director, namely, Mr. Zhang Ming Qi; a non-executive director, namely, Mr. Chen Qi; and four independent non-executive directors, namely, Ms. Huang Lin, Mr. Li Liang, Mr. Du Jianfeng and Mr. Tan Kaiguo.